Retinalamine® (Retinalamin®)

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Similar drugsTo uncover
Dosage form: & nbsp

Lyophilizate for solution preparation for intramuscular and parabulbar injection.

Composition:

One bottle contains

active substance - Retinalamine 5 mg (complex of water-soluble polypeptide fractions),

adjuvant - glycine 17 mg (stabilizer).

Description:

Lyophilized powder or porous mass of white or white with a yellowish tinge.

Pharmacotherapeutic group:Reparation of tissue stimulant
ATX: & nbsp
  • Other drugs for the treatment of eye diseases
    • Pharmacodynamics:

    Retinalamine - a complex of water-soluble polypeptide fractions with a molecular mass of not more than 10 000 Da.

    The drug has a stimulating effect on photoreceptors and cellular retinal elements, contributes to the improvement of the functional interaction of the pigment epithelium and the outer segments of photoreceptors, glial cells in dystrophic changes, accelerates the restoration of the light sensitivity of the retina. Normalizes vascular permeability, reduces the manifestations of local inflammatory reaction, stimulates reparative processes in diseases and injuries of the retina.

    The mechanism of action of RETHINAMINA® is determined by its metabolic activity: the drug improves the metabolism of the eye tissues and normalizes the functions of cell membranes, improves intracellular protein synthesis,regulates the processes of lipid peroxidation, promotes the optimization of energy processes.

    Pharmacokinetics:

    The composition of Retinalamina®, the active ingredient of which is a complex of polypeptide fractions, does not allow the usual pharmacokinetic analysis of its individual components.

    Indications:Compensated primary open-angle glaucoma, diabetic retinopathy, central retinal dystrophy of inflammatory and traumatic genesis, central retinal dystrophy, myopic disease (as part of complex therapy), central and peripheral taperotorhinal abiotrophy.
    Contraindications:Individual increased sensitivity to the components of the drug, age under 18 years - with compensated primary open-ended glaucoma, diabetic retinopathy, myopic disease (due to lack of of data by efficiency and safety); age up to 1 year - with central retinal dystrophy of inflammatory and traumatic genesis, central and peripheral taperotorhinal abiotrophy.
    Pregnancy and lactation:

    The drug is contraindicated in pregnancy (there is no data on efficacy and safety). If it is necessary to prescribe the drug during lactation, breastfeeding Feeding should be discontinued.

    Dosing and Administration:

    Adults with diabetic retinopathy, central retinal dystrophy of inflammatory and traumatic genesis, central and peripheral taperotorhinal abiotrophy parabulbarno or intramuscularly at 5-10 mg 1 time per day. The course of treatment - 5 - 10 days; if necessary, repeat after 3 - 6 months.

    With compensated primary open-angle glaucoma parabulbar or intramuscular 5 mg once a day. The course of treatment is 10 days; if necessary, repeat after 3-6 months.

    With myopic disease parabulbarno 5 mg once a day. The course of treatment is 10 days. It is recommended in combination with angioprotective and group B vitamins.

    The drug is dissolved in 1 - 2 ml of water for injection, 0.9% solution of sodium chloride or 0.5 % solution of procaine (novocain), directing the needle to the wall of the vial to avoid foaming.

    Children aged 1-5 years with central retinal dystrophy inflammatory and traumatic genesis, central

    and peripheral taperotorhinal abiotrophy parabulbar or intramuscularly 2.5 mg once a day.

    Children aged 6-18 years old at central retinal dystrophy inflammatory and traumatic genesis, central and peripheral taperotinal abiotrophy parabulbarically or intramuscularly 2.5 - 5.0 mg 1 time per day.

    The drug is dissolved in 1 - 2 ml of 0.9% solution of sodium chloride, directing Needle to the wall of the vial to avoid foaming. Course of treatment - 10 days; if necessary repeat in 3-6 months.

    Precautions for use

    Use RETINALAMIN® only as directed by your doctor!

    The bottle with dissolved medicinal product can not be stored and used after storage. The solution of RETINALAMIN® is not recommended for mixing with other solutions.

    Side effects:

    There were no known side effects.

    Allergic reactions are possible in case of individual hypersensitivity to the components of the drug.

    Overdose:

    No cases of drug overdose have been reported.

    Interaction:

    Drug interaction of the drug is not described.

    Special instructions:

    Features of the drug during the first admission or when it is canceled are absent.

    In the case of missed injections, it is not recommended to administer a double dose, but to carry out the next injection as usual on the target day.

    Special precautions for the destruction of unused medications are not required.

    Effect on the ability to drive transp. cf. and fur:

    The drug does not affect the ability to drive vehicles and mechanisms.

    Form release / dosage:Lyophilizate for solution preparation for intramuscular and parabulbar administration, 5 mg.
    Packaging:

    By 22 mg of lyophilizate in bottles with a capacity of 5 ml, 5 bottles into the contour cell packaging of the film PVC and aluminum foil. 2 contour squares in a pack of cardboard together with instructions for use.

    Storage conditions:

    In the dark place at temperature from 2 to 20 ° C.

    Keep out of the reach of children.
    Shelf life:

    3 years. Do not use after the expiry date printed on the package.

    Terms of leave from pharmacies:On prescription
    Registration number:LS-000684
    Date of registration:07.07.2010 / 12.12.2013
    The owner of the registration certificate:GEROPHARM, LLC GEROPHARM, LLC Russia
    Manufacturer: & nbsp
    Information update date: & nbsp10.02.16
    Illustrated instructions
      Instructions
      Up